While it is well established that NAFLD is associated with CVD in the general population, the association among individuals living with HIV is less well understood.
New research presented at CROI 2020 identified 3 high-risk behaviors and evaluated them via patient questionnaire among men who have sex with men in New York City.
After performance data showed 95% sensitivity and specificity, the FDA authorized the assay’s marketing in the United States for detection of HIV-1 drug-resistant mutations.
For the FLU-IVIG trial, researchers evaluated the safety and efficacy of anti-influenza hyperimmune intravenous immunoglobulin to better understand the clinical benefits for patients with influenza.
While it is known that disease progression of HIV-1 is delayed by HIV-2 in coinfected individuals, authors of a new study sought to identify the protective mechanisms of the coinfection.
With the aging HIV population, it is important to understand how inflammation and age-related comorbidities will affect treatment options in this population moving forward. This was the topic of Tuesday’s...
Results of a new study presented at CROI 2019, found the efficacy and safety of F/TAF versus F/TDF for PrEP in MSM and transgender women who are at high risk of HIV acquisition.
In this plenary session, Alexandra M. Oster, from the CDC, discusses molecular detection of HIV clusters, how the United States has used that data, and how researchers have responded to these clusters.
...
For his Bernard Fields Lecture at CROI 2019, Dr Michel C. Nussenzweig from the Rockefeller University in New York discussed the discovery and development of HIV broadly neutralizing antibodies.
